Abbott Laboratories (ABT) - Total Assets
Based on the latest financial reports, Abbott Laboratories (ABT) holds total assets worth $84.18 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABT net asset value for net asset value and shareholders' equity analysis.
Abbott Laboratories - Total Assets Trend (1985–2024)
This chart illustrates how Abbott Laboratories's total assets have evolved over time, based on quarterly financial data.
Abbott Laboratories - Asset Composition Analysis
Current Asset Composition (December 2024)
Abbott Laboratories's total assets of $84.18 Billion consist of 29.1% current assets and 70.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $7.62 Billion | 9.4% |
| Accounts Receivable | $6.92 Billion | 8.5% |
| Inventory | $6.19 Billion | 7.6% |
| Property, Plant & Equipment | $11.73 Billion | 14.4% |
| Intangible Assets | $6.65 Billion | 8.2% |
| Goodwill | $23.11 Billion | 28.4% |
Asset Composition Trend (1985–2024)
This chart illustrates how Abbott Laboratories's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Abbott Laboratories (ABT) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abbott Laboratories's current assets represent 29.1% of total assets in 2024, a decrease from 48.5% in 1985.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, down from 12.6% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 36.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 28.4% of total assets.
Abbott Laboratories Competitors by Total Assets
Key competitors of Abbott Laboratories based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Abbott Laboratories - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 1.60 | 1.72 |
| Quick Ratio | 1.24 | 1.14 | 1.30 |
| Cash Ratio | 0.52 | 0.51 | 0.00 |
| Working Capital | $10.26 Billion | $8.90 Billion | $8.53 Billion |
Abbott Laboratories - Advanced Valuation Insights
This section examines the relationship between Abbott Laboratories's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.85 |
| Latest Market Cap to Assets Ratio | 1.91 |
| Asset Growth Rate (YoY) | 11.2% |
| Total Assets | $81.41 Billion |
| Market Capitalization | $155.56 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Abbott Laboratories's assets above their book value (1.91x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Abbott Laboratories's assets grew by 11.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abbott Laboratories (1985–2024)
The table below shows the annual total assets of Abbott Laboratories from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $81.41 Billion | +11.20% |
| 2023-12-31 | $73.21 Billion | -1.64% |
| 2022-12-31 | $74.44 Billion | -1.01% |
| 2021-12-31 | $75.20 Billion | +3.65% |
| 2020-12-31 | $72.55 Billion | +6.87% |
| 2019-12-31 | $67.89 Billion | +1.06% |
| 2018-12-31 | $67.17 Billion | -11.90% |
| 2017-12-31 | $76.25 Billion | +38.61% |
| 2016-12-31 | $55.01 Billion | +25.02% |
| 2015-12-31 | $44.00 Billion | +0.48% |
| 2014-12-31 | $43.79 Billion | +1.95% |
| 2013-12-31 | $42.95 Billion | -36.12% |
| 2012-12-31 | $67.23 Billion | +11.54% |
| 2011-12-31 | $60.28 Billion | -0.49% |
| 2010-12-31 | $60.57 Billion | +15.20% |
| 2009-12-31 | $52.58 Billion | +23.96% |
| 2008-12-31 | $42.42 Billion | +6.81% |
| 2007-12-31 | $39.71 Billion | +9.77% |
| 2006-12-31 | $36.18 Billion | +24.15% |
| 2005-12-31 | $29.14 Billion | +1.30% |
| 2004-12-31 | $28.77 Billion | +7.68% |
| 2003-12-31 | $26.72 Billion | +10.13% |
| 2002-12-31 | $24.26 Billion | +4.13% |
| 2001-12-31 | $23.30 Billion | +52.43% |
| 2000-12-31 | $15.28 Billion | +5.61% |
| 1999-12-31 | $14.47 Billion | +9.49% |
| 1998-12-31 | $13.22 Billion | +9.58% |
| 1997-12-31 | $12.06 Billion | +8.41% |
| 1996-12-31 | $11.13 Billion | +18.20% |
| 1995-12-31 | $9.41 Billion | +10.43% |
| 1994-12-31 | $8.52 Billion | +10.86% |
| 1993-12-31 | $7.69 Billion | +10.77% |
| 1992-12-31 | $6.94 Billion | +10.97% |
| 1991-12-31 | $6.26 Billion | +12.44% |
| 1990-12-31 | $5.56 Billion | +14.67% |
| 1989-12-31 | $4.85 Billion | +0.55% |
| 1988-12-31 | $4.83 Billion | +10.02% |
| 1987-12-31 | $4.39 Billion | +13.45% |
| 1986-12-31 | $3.87 Billion | +11.45% |
| 1985-12-31 | $3.47 Billion | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more